bioMérieux S.A.

DB:EYW Stock Report

Market Cap: €10.7b

bioMérieux Management

Management criteria checks 4/4

bioMérieux's CEO is Alexandre Merieux, appointed in Dec 2017, has a tenure of 4.75 years. total yearly compensation is €1.53M, comprised of 38.5% salary and 61.5% bonuses, including company stock and options. directly owns 0% of the company’s shares, worth €5.37K. The average tenure of the management team and the board of directors is 4.5 years and 9.3 years respectively.

Key information

Alexandre Merieux

Chief executive officer

€1.5m

Total compensation

CEO salary percentage38.5%
CEO tenure4.8yrs
CEO ownership0.00005%
Management average tenure4.5yrs
Board average tenure9.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Alexandre Merieux's remuneration changed compared to bioMérieux's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2022n/an/a

€552m

Mar 31 2022n/an/a

€577m

Dec 31 2021€2m€588k

€601m

Sep 30 2021n/an/a

€555m

Jun 30 2021n/an/a

€509m

Mar 31 2021n/an/a

€457m

Dec 31 2020€1m€574k

€404m

Sep 30 2020n/an/a

€355m

Jun 30 2020n/an/a

€305m

Mar 31 2020n/an/a

€289m

Dec 31 2019€1m€538k

€273m

Sep 30 2019n/an/a

€268m

Jun 30 2019n/an/a

€263m

Mar 31 2019n/an/a

€260m

Dec 31 2018€1m€504k

€257m

Sep 30 2018n/an/a

€264m

Jun 30 2018n/an/a

€271m

Mar 31 2018n/an/a

€255m

Dec 31 2017€1m€462k

€238m

Sep 30 2017n/an/a

€216m

Jun 30 2017n/an/a

€195m

Mar 31 2017n/an/a

€187m

Dec 31 2016€1m€446k

€179m

Sep 30 2016n/an/a

€158m

Jun 30 2016n/an/a

€137m

Mar 31 2016n/an/a

€124m

Dec 31 2015€818k€401k

€111m

Compensation vs Market: Alexandre's total compensation ($USD1.52M) is below average for companies of similar size in the German market ($USD4.73M).

Compensation vs Earnings: Alexandre's compensation has been consistent with company performance over the past year.

CEO

Alexandre Merieux (48 yo)

4.8yrs

Tenure

€1,528,441

Compensation

Mr. Alexandre Merieux serves as the Chairman and Chief Executive Officer of bioMérieux, Inc. Mr. Merieux serves as the President and Chairman of the Management Board of Merieux Développement SAS. He joined...

Leadership Team

NamePositionTenureCompensationOwnership
Alexandre Merieux
Chairman & CEO4.8yrs€1.53m0.000050%
€ 5.4k
Pierre Boulud
Chief Operating Officer of Clinical Operations1.5yrs€1.24mno data
Frederic Beseme
Head of CSR2.7yrs€35.00k0.0025%
€ 266.5k
Guillaume Bouhours
Executive VP of Purchasing and Information Systems & CFO4.5yrsno datano data
Sylvain Morgeau
Investor Relationsno datano datano data
Valerie Leylde
Executive Vice President of Human Resources3.7yrsno datano data
François Lacoste
Executive Vice President of R&D4.5yrsno datano data
Mark Miller
Executive Vice President of Medical Affairs9.9yrsno datano data
Pierre Charbonnier
Executive Vice President of Quality4.5yrsno datano data
Yasha Mitrotti
Executive Vice President of Industrial Microbiology4.5yrsno datano data
Franck Admant
Director of Investor Relationsno datano datano data

4.5yrs

Average Tenure

49.5yo

Average Age

Experienced Management: EYW's management team is considered experienced (4.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Alexandre Merieux
Chairman & CEO18.4yrs€1.53m0.000050%
€ 5.4k
Alain Merieux
Founding Chairman5.1yrsno datano data
Jean-Luc Belingard
Non-Independent Director16yrs€43.00k0.051%
€ 5.5m
Philippe Archinard
Non-Independent Director12.3yrs€57.00k0.000030%
€ 3.2k
Harold Y. Boel
Independent Director10.3yrs€57.00k0.00013%
€ 14.0k
Agnes Lemarchand
Independent Director8.3yrs€42.00k0.00013%
€ 14.0k
Marie-Helene Habert-Dassault
Independent Director10.3yrs€46.00k0.000050%
€ 5.4k
Fanny Letier
Independent Director5.3yrs€41.00k0.000030%
€ 3.2k
Marie-Paule Kieny
Independent Director5.1yrs€35.00k0.00015%
€ 16.1k
Sylvain Orenga
Directorless than a yearno datano data

9.3yrs

Average Tenure

63yo

Average Age

Experienced Board: EYW's board of directors are considered experienced (9.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/09/07 10:28
End of Day Share Price 2022/06/10 00:00
Earnings2022/06/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

bioMérieux S.A. is covered by 34 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Armelle MoulinAlphaValue
Gaurav JainBarclays
Thomas JonesBerenberg